Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Holdings Increased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 175.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,714 shares of the biopharmaceutical company’s stock after buying an additional 4,911 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $1,477,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALNY. ANTIPODES PARTNERS Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 69.1% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after purchasing an additional 77,307 shares during the last quarter. DnB Asset Management AS grew its holdings in shares of Alnylam Pharmaceuticals by 102.3% during the third quarter. DnB Asset Management AS now owns 51,212 shares of the biopharmaceutical company’s stock valued at $9,070,000 after purchasing an additional 25,898 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock valued at $2,064,425,000 after purchasing an additional 30,608 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Alnylam Pharmaceuticals by 630.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after purchasing an additional 22,580 shares during the last quarter. Finally, Asset Management One Co. Ltd. grew its holdings in shares of Alnylam Pharmaceuticals by 41.3% during the fourth quarter. Asset Management One Co. Ltd. now owns 69,334 shares of the biopharmaceutical company’s stock valued at $13,569,000 after purchasing an additional 20,268 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ALNY shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, February 1st. Wolfe Research began coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Eight research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.12.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $148.50 on Friday. The stock has a market capitalization of $18.70 billion, a P/E ratio of -41.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1 year low of $143.52 and a 1 year high of $218.88. The business’s fifty day moving average is $153.99 and its two-hundred day moving average is $167.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. Alnylam Pharmaceuticals’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the company posted ($1.68) EPS. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.